XNASCDXC
Market cap443mUSD
Jan 27, Last price
5.81USD
1D
-2.35%
1Q
60.50%
Jan 2017
75.53%
IPO
48.97%
Name
Chromadex Corp
Chart & Performance
Profile
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
IPO date
Jun 25, 2007
Employees
113
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2016‑00 | |
Income | |||||||||
Revenues | 83,570 15.99% | 72,050 6.82% | |||||||
Cost of revenue | 89,169 | 90,678 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (5,599) | (18,628) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (2,091) | ||||||||
Tax Rate | |||||||||
NOPAT | (5,599) | (16,537) | |||||||
Net income | (4,938) -65.82% | (14,449) -43.46% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 7,747 | ||||||||
BB yield | -6.61% | ||||||||
Debt | |||||||||
Debt current | 1,404 | 696 | |||||||
Long-term debt | 5,852 | 7,818 | |||||||
Deferred revenue | 3,311 | 3,955 | |||||||
Other long-term liabilities | 3,955 | ||||||||
Net debt | (20,069) | (11,727) | |||||||
Cash flow | |||||||||
Cash from operating activities | 7,117 | (15,098) | |||||||
CAPEX | (148) | (334) | |||||||
Cash from investing activities | (143) | (334) | |||||||
Cash from financing activities | (90) | 7,654 | |||||||
FCF | 1,446 | (20,836) | |||||||
Balance | |||||||||
Cash | 27,325 | 20,241 | |||||||
Long term investments | |||||||||
Excess cash | 23,146 | 16,638 | |||||||
Stockholders' equity | (190,389) | (185,422) | |||||||
Invested Capital | 226,837 | 226,261 | |||||||
ROIC | |||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 74,985 | 69,729 | |||||||
Price | 1.43 -14.88% | 1.68 -55.08% | |||||||
Market cap | 107,229 -8.46% | 117,145 -53.38% | |||||||
EV | 87,160 | 105,418 | |||||||
EBITDA | (3,894) | (16,744) | |||||||
EV/EBITDA | |||||||||
Interest | 3 | ||||||||
Interest/NOPBT |